PD98059
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 401680

CAS#: 167869-21-8

Description: PD98059 also known as PD-98059, is a potent and selective inhibitor of MAP kinase kinase (also known as MAPK/ERK kinase or MEK kinase). It mediates its inhibitory properties by binding to the ERK-specific MAP kinase MEK, therefore preventing phosphorylation of ERK1/2 (p44/p42 MAPK) by MEK1/2. MAPK ERK1/2 is involved in TLR-induced production of cytokines.


Price and Availability

Size
Price

10mg
USD 150
100mg
USD 650
1g
USD 2850
Size
Price

25mg
USD 250
200mg
USD 950
2g
Ask price
Size
Price

50mg
USD 450
500mg
USD 1650
5g
Ask price

PD98059, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 401680
Name: PD98059
CAS#: 167869-21-8
Chemical Formula: C16H13NO3
Exact Mass: 267.08954
Molecular Weight: 267.28
Elemental Analysis: C, 71.90; H, 4.90; N, 5.24; O, 17.96


Synonym: PD98059; PD-98059; PD 98059; PD098059

IUPAC/Chemical Name: 2-(2-amino-3-methoxyphenyl)-4H-chromen-4-one

InChi Key: QFWCYNPOPKQOKV-UHFFFAOYSA-N

InChi Code: InChI=1S/C16H13NO3/c1-19-14-8-4-6-11(16(14)17)15-9-12(18)10-5-2-3-7-13(10)20-15/h2-9H,17H2,1H3

SMILES Code: O=C1C=C(C2=CC=CC(OC)=C2N)OC3=C1C=CC=C3


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


Additional Information

  
 
 
 


References

1: Huang CT, Huang DY, Hu CJ, Wu D, Lin WW. Energy adaptive response during parthanatos is enhanced by PD98059 and involves mitochondrial function but not autophagy induction. Biochim Biophys Acta. 2014 Mar;1843(3):531-43. PubMed PMID: 24321770.

2: Lee JM, Kim JD, Oh EJ, Oh SH, Lee JH, Im GI. PD98059-impregnated functional PLGA Scaffold for direct tissue engineering promotes chondrogenesis and prevents hypertrophy from mesenchymal stem cells. Tissue Eng Part A. 2014 Mar;20(5-6):982-91. doi: 10.1089/ten.TEA.2013.0290. Epub 2013 Dec 11. PubMed PMID: 24188591; PubMed Central PMCID: PMC3938927.

3: Pathania AS, Joshi A, Kumar S, Guru SK, Bhushan S, Sharma PR, Bhat WW, Saxena AK, Singh J, Shah BA, Andotra SS, Taneja SC, Malik FA, Kumar A. Reversal of boswellic acid analog BA145 induced caspase dependent apoptosis by PI3K inhibitor LY294002 and MEK inhibitor PD98059. Apoptosis. 2013 Dec;18(12):1561-73. doi: 10.1007/s10495-013-0889-4. PubMed PMID: 23948751.

4: Yao J, Qian C, Shu T, Zhang X, Zhao Z, Liang Y. Combination treatment of PD98059 and DAPT in gastric cancer through induction of apoptosis and downregulation of WNT/β-catenin. Cancer Biol Ther. 2013 Sep;14(9):833-9. doi: 10.4161/cbt.25332. Epub 2013 Jun 14. PubMed PMID: 23792588; PubMed Central PMCID: PMC3909552.

5: Han YH, Moon HJ, You BR, Yang YM, Kim SZ, Kim SH, Park WH. The MEK inhibitor PD98059 attenuates growth inhibition and death in gallic acid-treated Calu-6 lung cancer cells by preventing glutathione depletion. Mol Med Rep. 2010 May-Jun;3(3):519-25. doi: 10.3892/mmr_00000291. PubMed PMID: 21472273.

6: Cotrim CZ, Amado FL, Helguero LA. Estrogenic effect of the MEK1 inhibitor PD98059 on endogenous estrogen receptor alpha and beta. J Steroid Biochem Mol Biol. 2011 Mar;124(1-2):25-30. doi: 10.1016/j.jsbmb.2010.12.020. Epub 2011 Jan 12. PubMed PMID: 21236341.

7: Di Paola R, Crisafulli C, Mazzon E, Genovese T, Paterniti I, Bramanti P, Cuzzocrea S. Effect of PD98059, a selective MAPK3/MAPK1 inhibitor, on acute lung injury in mice. Int J Immunopathol Pharmacol. 2009 Oct-Dec;22(4):937-50. PubMed PMID: 20074457.

8: Di Paola R, Galuppo M, Mazzon E, Paterniti I, Bramanti P, Cuzzocrea S. PD98059, a specific MAP kinase inhibitor, attenuates multiple organ dysfunction syndrome/failure (MODS) induced by zymosan in mice. Pharmacol Res. 2010 Feb;61(2):175-87. doi: 10.1016/j.phrs.2009.09.008. Epub 2009 Oct 9. PubMed PMID: 19819333.

9: Al-Shanti N, Stewart CE. PD98059 enhances C2 myoblast differentiation through p38 MAPK activation: a novel role for PD98059. J Endocrinol. 2008 Jul;198(1):243-52. doi: 10.1677/JOE-08-0151. Epub 2008 May 8. PubMed PMID: 18467380.

10: Kanda S, Kanetake H, Miyata Y. Long-term exposure of human renal carcinoma cells to PD98059 induces epithelial-mesenchymal transition-like phenotype and enhanced motility. Mol Cell Biochem. 2008 Feb;309(1-2):69-76. Epub 2007 Nov 14. PubMed PMID: 18000741.